Impact of ethnicity on primary treatment choice and mortality in men with prostate cancer: data from CaPSURE.

PURPOSE Men diagnosed with prostate cancer have multiple options available for treatment. Previous reports have indicated a trend of differing modalities of treatment chosen by African American and white men. We investigated the role of ethnicity in primary treatment choice and how this affected overall and cancer-specific mortality. METHODS By utilizing data abstracted from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE), patients were compared by ethnicity, primary treatment, number of comorbidities, risk level according to modified D'Amico criteria, age, highest educational level attained, type of insurance, treatment facility, and perception of general health. Multinomial logistic regression analysis was performed to determine the effect of the tested variables on primary treatment and mortality. Results African American men were more likely to receive nonsurgical therapy than white men with equivalent disease characteristics. Whites were 48% less likely than African Americans to receive androgen deprivation therapy (ADT) compared with surgery (P = .02) and were 25% less likely than African Americans to receive radiation therapy compared with surgery (P = .08). Whites with low-risk disease were 71% less likely to receive ADT than African American men with similar disease (P = .01). Adjusted overall and prostate cancer-specific mortality were not significantly different between whites and African Americans (hazard ratios, 0.73 and 0.37, respectively). Risk level, type of treatment, and type of insurance had the strongest effects on risk of mortality. CONCLUSION There is a statistically significant difference in primary treatment for prostate cancer between African American and white men with similar risk profiles. Additional research on the influence of patient/physician education and perception and the role that socioeconomic factors play in mortality from prostate cancer may be areas of focus for public health initiatives.

[1]  Jim C Hu,et al.  Determinants of treatment regret in low-income, uninsured men with prostate cancer. , 2008, Urology.

[2]  R. deVere White,et al.  Racial differences in clinically localized prostate cancers of black and white men. , 1998, The Journal of urology.

[3]  John T. Wei,et al.  Postprostatectomy cancer-free survival of African Americans is similar to non-African Americans after adjustment for baseline cancer severity. , 2004, Urologic oncology.

[4]  D. Johnston,et al.  Prostate specific antigen and pathological features of prostate cancer in black and white patients: a comparative study based on radical prostatectomy specimens. , 1998, The Journal of urology.

[5]  W. Sakr,et al.  Outcome of African American men screened for prostate cancer: the Detroit Education and Early Detection Study. , 1997, Journal of Urology.

[6]  M. Cooperberg,et al.  Differences in clinical characteristics and disease‐free survival for Latino, African American, and non‐Latino white men with localized prostate cancer , 2006, Cancer.

[7]  John T. Wei,et al.  Racial/ethnic disparities in the treatment of localized/regional prostate cancer. , 2004, The Journal of urology.

[8]  P. Carroll,et al.  Androgen‐deprivation therapy as primary treatment for localized prostate cancer , 2006, Cancer.

[9]  Colin B Begg,et al.  Survival of blacks and whites after a cancer diagnosis. , 2002, JAMA.

[10]  I. Powell.  Epidemiology and pathophysiology of prostate cancer in African-American men. , 2007, The Journal of urology.

[11]  Ruth Etzioni,et al.  Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999. , 2004, Urology.

[12]  M. Menon,et al.  Effect of socioeconomic factors on long-term mortality in men with clinically localized prostate cancer. , 2009, Urology.

[13]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[14]  A. Jemal,et al.  Recent Trends in Black-White Disparities in Cancer Mortality , 2008, Cancer Epidemiology Biomarkers & Prevention.

[15]  F. Gilliland,et al.  Racial differences in initial treatment for clinically localized prostate cancer , 2003, Journal of General Internal Medicine.

[16]  M. Banerjee,et al.  The effect of race/ethnicity on prostate cancer treatment outcome is conditional: a review of Wayne State University data. , 2004, The Journal of urology.

[17]  J. Stanford,et al.  Factors associated with initial therapy for clinically localized prostate cancer: prostate cancer outcomes study. , 2001, Journal of the National Cancer Institute.

[18]  S. Freedland,et al.  The role of primary androgen deprivation therapy in localized prostate cancer. , 2009, European urology.

[19]  A. Araujo,et al.  Explaining the Race Difference in Prostate Cancer Stage at Diagnosis , 2008, Cancer Epidemiology Biomarkers & Prevention.

[20]  Desok Kim,et al.  Racial differences in androgen receptor protein expression in men with clinically localized prostate cancer. , 2003, The Journal of urology.

[21]  S. Ramsey,et al.  Why do men choose one treatment over another? , 2006, Cancer.

[22]  M. Schapira,et al.  Treatment of Localized Prostate Cancer in African‐American Compared with Caucasian Men; Less Use of Aggressive Therapy for Comparable Disease , 1995, Medical care.

[23]  Jorge A. Garcia,et al.  Complications of androgen deprivation therapy in prostate cancer. , 2009, Current opinion in urology.

[24]  R. Severson,et al.  Impact of a genetic variant in CYP3A4 on risk and clinical presentation of prostate cancer among white and African-American men. , 2006, Urologic oncology.